Fachinformationen zu aminoplus cor - Kyberg Vital

Literatur
[1] Osiecki H. The role of Chronic inflammation in Cardiovascular Disease and its regulation by Nutrients. Alternative Medicine Review 2004;
9:32-53.
[2] Landmesser U, Hornig B, Drexler H. Endothelial Function – A Critical Determinant of Arteriosklerosis? Circulation 2004; 109:27-33.
[3] Weis M, Schlichting CL, Engleman EG, Cooke JP. Endothelial Determinants of Dentritic Cell Adhesion and Migration-New Implications for
Vascular Diseases. Arteriosclerosis Thrombocyte Vascular Biology 2002; 22:1817-23.
[4] Beyond discovery – NO. www.nationalacademies.org/germanbeyonddiscovery/Stickoxid 2003.
[5] Tousoulis D, Antoniades C,Tentolouris C, Goumas G, Stefanadis C,Toutouzas P. L-Arginine in cardiovascular disease: dream or reality? Vascular
Medicine 2002; 7:203-11.
[6] Doshi S, McDowell I, Moat S, Lewis M, Goodfellow J. Folate improves Endothelial Function in Patients with Coronary Heart Disease. Clinical
Chemical Laboratory Medicine 2003; 41:1505-12.
[7] Cooke JP,Tsao PS. Go with the flow. Circulation 2001; 103:2773-5.
[8] Niebauer J, Maxwell AJ, Lin PS,Wang D, Tsao PS, Cooke JP. NOS inhibition accelerates aterogenesis: reversal by exercise. American Journal
of Physiology- Heart and Circulatory Physiology 2003; 285:H535-H540.
[9] Matsushita H, Chang E, Glassford AJ, Cooke JP, Chiu CP,Tsao PS. eNOS Activity Is Reduced in Senescent Human Endothelial Cells. Circulation
Research 2001; 89:793-8.
[10] Cooke JP. Does ADMA Cause Endothelial Dysfunction. Arteriosclerosis Thrombocyte Vascular Biology 2000; 20:2032-7.
[11] Rytlewski K, Olszanecki R, Korbut R, Zdebski Z. Effects of prolonged oral supplementation with L-arginine on blood pressure and nitric
oxide synthesis in preclampsia. European Journal of Clinical Investigation 2005; 35:32-7.
[12] Wolf A, Zalpour C,Theilmeier G et al. Dietary L-Arginine Supplementation Normalize Platelet Aggregation in Hypercholesterolemic
Humans. Journal of Americal College of Cardiology 1997; 29:479-85.
[13] Schulmann SP, Becker LC, Kass DA et.al. L-Arginin therapy in acute myocardial infarction. The vacular interaction with age in mycoardia!
Vintage MI randomzied clinical trial. Journal American Medical Association 2006; 295:58-64.
[14] Vasquez-Vivar J, Kalyanaraman B, Martasek P et al. Superoxide generation by endothelial nitric oxide synthase: The influence of cofactors.
The National Academy of Sciences 1998; 95:9220-5.
[15] Alp NJ, Channon KM. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vasular disease. Arteriosclerosis Thrombocyte
Vascular Biology 2004; 24:413-20.
[16] Cooke JP, Oka RK. Atherogenesis and the Arginine Hypothesis. Current Atherosclerosis Reports 2001; 3:252-9.
[17] Rybalkin SD,Yan C, Bornfeldt KE, Beavo JA. Cyclic GMP Phosphodiesterases and Regulation of Smooth Muscle Function. Circulation Research
2003; 93:280-91.
[18] Hutchison S, Sudhir K, Sievers RE et al. Effects of L-Arginin on Atherogenesis and Endothelial Dysfunction due to Secondhand Smoke.
Hypertension 1999; 34:44-50.
[19] Dayoub H, Achan V, Adimoolam S et al. Dimethylarginine: Dimethylaminohydrolase Regulates Nitric Oxide Synthesis - Genetic and Physiological
Evidence. Circulation 2003; 108:3042-7.
[20] Jang JJ, Boai-Ky BA, Kwan HH, Fajardo LF, Cooke JP. Angiogenesis is impaired by Hypercholesterolemia - Role of Asymmetric Dimethylarginine.
Circulation 2000; 102:1414-9.
[21] Stuehlinger M,Tsao PS, Jeng-Horng H, Kimoto M, Balint RF, Cooke JP. Homocystein impairs the nitric oxide Synthase Pathway - Role of
asymmetric Dimethlyarginine. Circulation 2003; 108:933-8.
[22] Cooke JP. Asymmetrical Dimethylarginine - The über Marker?. Circulation 2004; 109:1813-9.
[23] Boeger RH, Bode-Boeger SM. Is Asymmetric Dimethylarginin a novel marker of atheriosklerosis? - comment. Circulation 2000; 101:160.
[24] Stuehlinger M, Roberta K, Graf EE et al. Endothelial Dysfunction induced by Hyperhomocysteinemia - Role of asymmetric Dimethylarginine.
Circulation 2003; 108:933-8.
[25] Xia J, May F, Koschinsky M. Characterization of the basis of lipoprotein(a) lysine-binding heterogeneity. Journal of Lipid Research 2000;
41:1578-84.
[26] Tsurupa G, Noes B, Angles-Canot E, Medved L. Identification and Characterisation of Novel Lysine - independent Apolipoprotein(a)binding
Sites in Fibrin(ogen) alpha C-Domains. The Journal of Biological Chemistry 2003; 278:37154-9.
[27] Boonmark NM, Lawn RM. The Lysinebindingfunction of Lp(a). Clinical Genetics 1997;52:355-60.
[28] Rath M, Pauling L. Hypothesis: Lipoprotein(a) is a surrogate for ascorbate. Proceedings of National Academie of Science USA 1990;
87:6204-7.
[29] Dalessandri KM. Reduction of Lp(a) in postmenopausal women. Archives of Internal Medicine 2001; 161:772-3.
[30] Griffith RS, Nornins AL, Kagan C. A Multicentered Study of Lysine Therapy in Herpes simplex Infektionen. Dermatologica 1978; 156:257-67.
[31] McCune, Perry HO,Muller SA, O'Fallon WM. Treatment of recurrent herpes simplex infections with L-Lysine-monohydrochlorid. Cutis 1985;
34:366-73.
[32] Millman N, Scheibel J JO. Lysine prophylaxis in recurrent herpes simplex labialis. Acta Derm Venereol 1980; 60:85-7.
[33] Thein DJ, Hurt WJ. Lysine as a prophylactic agent in the treatment of recurrent herpes simplex labialis. Oral Surg.Oral Med Pathol 1984;
58:659-66.
[34] Arndt K, Albers T. Handbuch Protein und Aminosäuren. Novagenics Verlag, Arnsberg, 2001.
[35] Reglin F. Homocysteinämie. In: Ralf Reglin Verlag, ed. Bausteine des Lebens. Köln: 1999:209-13.
[36] Niacin. In: Umschau / Braus, ed. Referenzwerte für die Nährstoffzufuhr. Deutsche Gesellschaft für Ernährung (DGE) 2000:109-12.
[37] Kostner GM. Lipoprotein(a): Metabolismus und Beeinflussung des Plasmaspiegels. Journal für Kardiologie 2002; 9:321-4.
[38] Nikotinsäure treibt den HDL-Wert in die Höhe. Ärztezeitung 2005; 24.06.05.
[39] Taddei S.,Virdis A., Ghiadoni L. MASA.Vitamin C improves Endothelium-Dependent Vasodilation by restoring Nitric Oxide Activity in essential
Hypertension. Circulation 1998; 97:2222-9.
[40] Hillstrom RJ,Yacapin-Ammons AK, Lynch SM. Vitamin C inhibits Lipid Oxidation in Human HDL. Journal of Nutrition 2003; 133:3047-51.
[41] d«Usicio LV, Milstien S, Richardson D, smith L KZ. Long-Term Vitamin C Treatment of Vitamin C Increases VascularTetrahydrobiopterin Levels
and Nitric Oxide Synthetase Activity. Circulation Research 2003; 92:88-95.
[42] Chambers JC, McGregor A, Jean-Marie J, Obeid OA, Kooner JS. Demonstration of Rapid Onset Vascular Endothelial Dysfunction After
Hyperhomoysteinaemia- An Effect Reversible With Vitamine C Therapy. Circulation 1999; 99:1156-60.
[43] Desideri G, Marinucci MC,Tomassoni G, Masci PC, Santucci A, Feri C. Vitamin E supplementation reduces plasma Vascular Cell Adhesion
Molecule-1 and von Willebrand Factor levels and increases Nitric oxide Concentration in Hypercholesterolemic patients. The Journal of
Clinical Endocrinology & Metabolism 2002; 87:2940-5.
14 Literatur
Literatur 15